USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Comment Letter: Submitted to DEA on Schedules of Controlled Substances: Rescheduling of Marijuana
USP Comment Letter Submitted to DEA on July 24, 2024 regarding schedules of Controlled Substances: Rescheduling of Marijuana (Docket No. DEA-2024-0059; A.G. Order No. 5931-2024). Learn More
USP Comment Letter: Submitted to Congress on CURES 2.0 Request for Information (August 2024)
USP Comment Letter submitted to Congress on CURES 2.0 Request for Information. Submitted on August 2, 2024 Learn More
USP Comment Letter: Submitted to DEA for Schedules of Controlled Substances: Rescheduling of Marijuana (July 2024)
USP Comment Letter: Submitted to DEA for Schedules of Controlled Substances: Rescheduling of Marijuana; (Docket No. DEA-2024-0059; A.G. Order No. 5931-2024). Submitted on July 22, 2024. Learn More
USP Comments on the Senate Finance Committee’s Legislative Draft "Drug Shortage Prevention and Mitigation Act” (2024)
Learn More
USP Comment Letter to Office of the National Coordinator for Health Information Technology (ONC) regarding 2024-2030 Federal Health IT Strategic Plan (2024)
Learn More
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002)
USP Comment Letter: Submitted to Office of the United States Trade Representative on Comments on Promoting Supply Chain Resilience (USTR-20240002) (2024) Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024. Learn More
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience
USP Global Policy Position: Excipients: A Blind Spot in Ensuring Medicine Quality and Supply Chain Resilience; Published 2024 Learn More
USP Comment Letter: Submitted to FDA on NDI Draft Guidance (2011)
The USP submits comments to the Draft Guidance for Industry; Dietary Supplements: New Dietary Ingredient Notifications and Related Issues (“Guidance”) published by the Food and Drug Administration (… Learn More
USP Global Public Policy Position: Identifying and addressing vulnerabilities in the upstream medicines supply chain to build resilience and reduce drug shortages
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical… Learn More

Document Classification

Topics